When logarithmically growing neuroblastoma cells were exposed in vitro for 24 hr to a range of concentrations of various antitumour drugs and then cloned in agar to assess colony-forming ability, the dose-response curves obtained were of two types only, namely exponential-plateau or exponential. The former category, included hydroxyurea, 1.1'-propylene bispiperazine-3.5-dione (ICRF-159). vincristine and vindesine. where the plateau was reached before 1 log cell kill, and 4'-demethylepipodophllotoxin thenylidine glucoside (NSC 122819) (VM-26) and 4'-demethyle p i p o d o p h l l o t o x i n -9 -( 4 , 6 -o e t h y l i d i n e -~y r a n o d e (NSC 141540) . where the plateau occurred at approximately 5% survival. Exponential survival curves were obtained with actinomycin D, Adriamycin, bleomycin, cis-dichlorodiammine platinum (11) (cis-platinum), dihromodulcitol, Ifluorouracil, 4'-(9-acridinylamino)methanesuIfon-m-anisidine (NSC 249992) (mAMSA), melphalan, and peptichemio. A comparison of drug concentrations required to reduce survival in vitro by 70%. with a 2 4 h r drug exposure, was attempted with those concentrations achievable as plasma levels in man after conventional drug therapy. The results obtained, after many and varied assumptions, allowed the division of the drugs tested into three main groups: (1) most effective agents, including mAMSA, VM-26, and Adriamycin; (2) agents with some activity-vincristine, vindesine, VP-16-213, cis-platinum, melphalan, and peptichemio, although only when the latter three drugs were used at the higher dosage levels; (3) agents with little, if any, activity-actinomycin D. bleomycin, dibromodulcitol, 5-fluorouracil, hydroxyurea, and ICRF-159. In terms of attempting clinical correlations, available data suggest definite value in treat-, ing neurohlastoma with VM-26 and Adriamycin [from our group ( I ) ) and also with vincristine, melphalan (high dose), peptichemio, and cis-platinum [from our group (2)l. No significant clinical activity has been reported for actinomycin D nor for bleomycin in previously treated children, and both these drugs proved negative in this model test system. Among the newer agents tested experimentally, our results suggest that although clinical evaluation of mAMSA, VP-16-213, and vindesine might be profitahle, dibromodulcitol and ICRF-159 may prove inactive.
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Speculation
The dismal prognosis for the majority of children with neuroblastoma serves to highlight the need for new and more effective therapies. One approach is to attempt to screen experimentally in vitro for drugs effective in this disease, Our preliminary studies, using only one cell line derived from one portion of a human tumour, have suggested, with many reservations, some correlations between in virro and clinical data. This work is now being extended to consider other human neuroblastoma cell lines and to monitor retrospectively drug responses in vitro with clinical responses. These studies are essential before any attempts are made to extrapolate any of the in ~i t r o results to humans. ~eurobladtoma is the most common extracranlal malignant solid tumou of infancy and childhood (20) . In contrast to the major adva 1 ces which have occurred in the treatment of other childhood cdncers, the prognosis for this disease remains poor ( 15. 20) . The majbrity are children over one year of age with metastatic disease, and despite initial responses to chemotherapy. the prognosis is dismal with 2-year survival figures of less than lo?. Several agents have been reported as active in neuroblastoma. but patient numt3ers are small (20) . Many single agents have not been tested, and few drug combinations have been adequately evaluated.
Attempts tb screen experimentally specifically for agents effective in this disease have not been widely reported. Finkelstein el al. (14) described some promising preliminary studies with the C1300 murink neuroblastoma system, but the relationship between human and nhurine neuroblastoma is uncertain. Specific screening potentially niay be a valuable approach in view of the apparent heterogenous nature of this tumour. including drug-resistant populations and b large nonproliferating pool of cells which may be less responsiSe to certain antitumour agents (17, 44) . The more recent studiei by Salmon et al. (37) have, however, raised great interest in in vitro drug sensitivity testing. This group has developed a hum I stem cell assay system which allows the response of an individtlal patient's tumour to a particular anticancer drug to be predicted with a very high degree of accuracy for certain tumour types, for example, ovarian cancer and melanoma. This work is now being extended by other groups, and further tumour types are being investigated (1, 8, 9, 16, 36, 43) . We are presently attempting siknilar studies using biopsy material from human neuroblastomas, but this material is not readily available, quantities are limited as are the number of patients available for study. and our cloning efficiencies are low, being of the order of 0.01% (35) . which of necessity restricts the number of drugs which it is possible to stpdy. Therefore, we decided initially to work with established hqman neuroblastoma cell cultures. Initially, we have (I) evaluated lthe effectiveness of a range of anti-tumour drugs in reducing the qlony-forming ability of human neuroblastoma cells in vitro and (2) attempted correlations between the effective lethal concentrations in vitro with those achievable clinically.
I MATERIALS A N D METHODS

I
CHEMICALS
The drugs baed, their solvents. and their sources are listed in Table I . --' All the drugs were dissolved in phosphate-buffered saline or Roswell Park Memorial Institute 1640 tissue culture medium with the exception of ( I ) dibromodulcitol. which was solubilized in a minimum quantity of dimethyl sulfoxide and then diluted to less than 0.1% in Roswell Park Memorial Institute I640 medium before adding to cultures; (2) melphalan, which was solubilized in a minimum quantity of 4.5% (w/v) ethanolic HCI and then diluted at least X50 in Roswell Park Memorial Institute 1640 medium before addition to cultures: and (3) 4'-(9-acridiny1amino)-methanesulfon-m-anisidide (NSC 249992), for which the diluent was 0.0353M L-lactic acid.
'The abbreviations used are: mAMSA, 4'-(9-acridiny1amino)-methanesulfon-m-anisidie (NSC 249992); cis-platinum, cis-dichlorodiammine platinum(1l): ICRF-159, 1.1'-propylene bispiperazine-3,5-dione;
. . VM-26, 4'-demethylepipodophlloto~n thenylidi"e glucoside (NSC 122819); VP-16-213. 4'-demethylepipodophIlotoxin-9-(4,6-oethylidine-~-D-glucopyranoside) (NSC 141540) cells, which was obtained from Dr. H. R. Schlesinger, The Children's Hospital, Philadelphia, PA, has been maintained in our laboratory for the last 12 months with weekly passaging and kept in liquid-nitrogen storage. Since the initial characterization of this cell line (38) , the later passage cells used in these present experiments differ in two respects: ( I ) under our culture conditions the population doubling time is approximately 22 hr and (2) treatment with trypsin and careful mechanical aspiration results in a uniform single cell suspension.
Cells were routinely monitored for the presence of Mycoplasma by testing for growth on nutrient agar and by direct microscopy of the aceto-orcein stained monolayers. Only data obtained using Mycoplasma-free cultures is presented. Metaphase preparations of these neuroblastoma cells provided evidence of their human chromosome pattern and the absence df cells of murine origin.
AGAR COLONY-FORMING ASSAYS
The colony-forming assays were performed as follows: initial dose-response curves of the cells, growing as monolayers, to a 24-hr drug exposure were obtained by cell counts on 5 successive days. From these data, for each drug tested, the appropriate concentration ranges were selected, and the approximate log cell kill produced was calculated. This enabled the number of cells plated in the viability assays to be varied so that approximately 100 colonies per tube were obtained for counting. In these assays. the cells used were in logarithmic growth when exposed to the selected range of drug concentrations for 24 hr only, after which the medium was removed. The CHPIOO cells were then washed with serum-free medium, trypsinized (0.25% trypsin as Tryptar from Armour Pharmaceuticals Co. Ltd., Eastbourne, United Kingdom) and resuspended in fresh Roswell Park Memorial Institute medium containing 10% fetal calf serum at 37OC. The appropriate number of cells were then added in I ml to 15 ml plastic tubes (Sterilin; Teddington, Middlesex, United Kingdom), and 5 mi of an agarose-containing mixture prepared in medium plus 10% fetal calf serum were added. The final agarose concentration was 0.17%. The cells were then incubated at 37OC in an atmosphere of 10% C02-90% air for approximately 3 wk before colony counting. The cloning efficiency of CHP100 cells was approximately 25 to 40%.
Treated cultures are expressed as a percentage of the control (nontreated or solvent-treated) cultures, which were given the value of 100%. The mean f S.E. of colony counts from replicate cultures, with each experiment repeated twice, were calculated, and survival curves were plotted on a semilogarithmic scale with the percentage surviving fraction against drug concentration.
RESULTS
The dose-response curves obtained following a 24-hr drug exposure are shown in Figures 1 and 2 . The drugs selected can be divided into two main groups, based on the shape of the dose- response curve obtained under these conditions. namely exponen-killing effectiveness with this particular group of agents for a fixed tial-plateau or exponential. In the former group, the plateau region time of exposure. Figure I contains the results obtained with these is reached before a I log cell kill is achieved for all the drugs tested drugs where the survival curves after a 24-hr drug exposure. with the exception of the podophyllotoxin derivatives, where the plateau irrespective of increasing drug concentrations. It should plateau occurs at approximately 5 % This suggests a limited cell be noted that approximately three times more vindesine is required Table 2 . A comparison of in vitro drug concentrations required to reduce survival b~ 70% with those plasma levels achievable clinicallv " Calculated by dividing the plasma levels by the in vilro concentrations.
than vincristine to achieve an equivalent cell kill. Because the clinical dosage of vindesine is conventionally approximately three times greater than that for vincristine, on a mg/m2 basis. this suggests equal effectiveness for these two Vinca alkaloids in this model system. However. approximately six times more 4'-deme-
thylepipodophllotoxin-9-(4.6-oethylidine-~-~-glucopyranoside)
(NSC 141540) (VP-16-213) is required than 4'-demethylepipodophllotoxin thenylidine glucoside (NSC 1228 19) (VM-26) to achieve an equivalent cell kill, suggesting superiority for VM-26, especially because the clinical dosage of VM-26 is conventionally approximately twice that for VP-16-213. Figure 2 illustrates the results obtained with drugs where increasing drug concentrations result in increasing cell kill. In this figure, it can be seen that similar concentrations of peptichemio and melphalan achieve comparable extents of cell kill. Because 100 mg of peptichemio are considered to contain only 40 mg equivalents of melphalan, this observation suggests superiority for peptichemio in this test system.
In an attempt to establish whether the sensitivity of these neuroblastoma cells in culture to various anti-tumour agents could provide any information as to the clinical usefulness of certain specific drugs, a comparison of drug concentrations required to reduce survival by 70% with a 24-hr exposure was attempted with those concentrations achievable as peak plasma levels in man after conventional drug therapy. This figure of 70% reduction is used by Alberts et al. ( I ) and Salmon et al. (36, 37) to predict sensitivity in their human tumour stem cell assays. Our results are listed in Table 2 . The maximum peak plasma levels have been calculated using standard single clinical drug doses and assuming maximum distribution in 1.2 litres of plasma at "zero time," except where specific published data are already available (18, 46) . The "N" factor in the last column has been obtained by dividing the suggested plasma levels achieved by the in vitro inhibitory drug concentration. Therefore. after these many and varied assumptions, this factor provides a suggested degree of efficacy for each drug tested. Using these data, it is possible to separate the drugs into three groups as shown in Table 3 , namely the most effective agents, those with intermediate effectiveness, and those with low "N" values. A similar grouping of "effectiveness" is obtained if the clinical drug levels are estimated according to the procedure recommended by 1,imburg and Heckmann (2 I ) who assumed the total drug dosage was distributed in plasma only. 
DISCUSSION
The effects of drugs on cell survival can be reliably estimated by colony-forming assays. These data are highly reproducible from experiment to experiment. and we obtained no evidence of any alterations in drug sensitivities after maintaining the cells in culture for one year nor after their recovery from storage in liquid nitrogen. Viability assays using colony formation in semisolid agar tend not only to be very time consuming to set up but also do not provide rapid results because at least 14 days are required for colony growth before assessment. However, this procedure is considered the best available technique for accurately determining cell kill (3, 34) , providing a far more reliable estimation of reproductive ability than simpler methods based purely on total cell counts or the exclusion of vital dyes such as trypan blue. The patterns of cell survival after 24 hr exposure to the various drugs tested confirm the division of drugs as Class I1 and Class I11 agents originally proposed by W. R. Bruce et al. (7) and extended subsequently by other authors (19, 23, 31, 32, 42) when they suggested the Kinetic Classification of Anti-tumour Drugs. A knowledge of this classification already has proven value in designing safer clinical chemotherapy protocols (19, 28, 29) . The administration of drug combinations over approximately 24 hr rather than several days has been shown to reduce the toxicity without compromising antiturnour effectiveness. When designing such combinations, it has been found that the toxicity of Class I1 agents to normal stem cells (e.g., bone marrow) is not dosedependent. Class I1 drugs therefore may be added to combinations without reducing their dose, provided the total treatment time is approximately 24 hr. Combinations of Class I11 drugs will be additively toxic to normal bone marrow, and therefore, doses should be reduced proportionately (19) . These present data therefore provide evidence that this Kinetic Classification can also be derived from studies using human tumour colony-forming cells in vitro. This simple model system may therefore be more convenient than the original spleen colony assay procedure, especially for testing new agents and determining whether they belong in Class I1 or Class Ill.
Finally, we have tried to correlate these laboratory data with available clinical information (see Table 4 ), as to the value of these drugs as single agents in the treatment of neuroblastoma. Information is not available on all the drugs we have tested experimentally, but Table 4 contains the information for those that have been evaluated clinically in this disease. These results suggest that the most effective agents in the clinic include cisdichlorodiammine platinum (11), VM-26, Adriamycin, and peptichemio and melphalan at higher doses, with some value also claimed for vincristine. Our laboratory data (see Table 3 ) also selects these agents as effective in vitro together with 4'-(9-acridinylamino)methanesulfon-m-anisidine (NSC 249992), VP-16-2 13. and vindesine, drugs which have not yet received clinical evaluation against this disease. In addition. actinomycin D which has been evaluated as not effective clinically also has a low N factor from in vitro studies, as does bleomycin, which was shown clinically to be of no benefit in combinatioin with vincristine in previously treated children with metastatic disease (2).
Attempts to relate in vitro drug sensitivity to clinical responses are complicated by the lack of adequate pharmacologic data in man. There is a definite requirement for detailed knowledge, not only of plasma drug levels but more particularly of tumour drug levels if such correlations are to be meaningful. It is also essential to remember that the experimental studies presented involved the use of only one line of human neuroblastoma cells derived from a single clinical specimen. These particular cells therefore may be in no way representative, either of the total tumour from which the line was derived or indeed from any other tumour from other patients, as regards response to chemotherapy. However, with these many reservations and bearing in mind the simplifications and assumptions which have been made in this paper, it would appear that some correlations between this initial ;n vitro work and clinical studies have been noted. Our results suggest that a further evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidine (NSC 249992), VP-16-213, and vindesine might be worthwhile. However, I. l '-propylene bispiperazine-3,5-dione and dibromodulcitol proved ineffective experimentally in this model system. Unfortunately, we were not able to study the effects of cyclophosphamide, a drug widely used with beneficial results in this disease (20, 24) because the drug requires metabolic activation, and it is unsuitable therefore for in vitro studies. A similar problem exists for dimethyltriazeno-imidazole-carboxamide for which some activity has also been reported (20) .
However. we are encouraged by these preliminary results and feel that further investigations are warranted in other human neuroblastoma cell lines to determine how reproducible and significant these preliminary data are and are hopeful of using human tumour biopsy material directly to check the drug sensitivities of individual patient's tumours.
